徕博科(LH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LH 徕博科

盘前交易 10-01 04:57:08 EDT

308.11

-0.70

-0.23%

最高311.54	最低306.98	成交量64.62万
今开311.00	昨收308.81	日振幅1.48%
总市值249.26亿	流通市值248.03亿	总股本8,090万
成交额2.00亿	换手率0.80%	流通股本8,050万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LH","market":"US","secType":"STK","nameCN":"徕博科","latestPrice":308.11,"timestamp":1790798400000,"preClose":308.81,"halted":0,"volume":646178,"delay":0,"changeRate":-0.0022667659726044774,"floatShares":80502000,"shares":80900000,"eps":12.076528,"marketStatus":"盘前交易","change":-0.7,"latestTime":"10-01 04:57:08 EDT","open":311,"high":311.54,"low":306.98,"amount":199563326.04988,"amplitude":0.014766,"askPrice":492.33,"askSize":40,"bidPrice":305.63,"bidSize":4,"shortable":3,"etf":0,"ttmEps":12.076528,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790861400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":672379200000,"exchange":"NYSE","adjPreClose":308.11,"dividendRate":0.009347,"postHourTrading":{"tag":"盘后","latestPrice":308.2,"preClose":308.11,"latestTime":"19:30 EDT","volume":43442,"amount":13384926.4193,"timestamp":1790811007560,"change":0.09,"changeRate":0.000292,"amplitude":0.000292},"volumeRatio":0.825967291523103,"impliedVol":0.2712,"impliedVolPercentile":0.516},"requestUrl":"/m/hq/s/LH","defaultTab":"news","newsList":[{"id":"1188000667","title":"徕博科在2026年投资者日强调推动持续增长与股东价值的战略优先事项","url":"https://stock-news.laohu8.com/highlight/detail?id=1188000667","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188000667?lang=zh_cn&edition=full","pubTime":"2026-09-10 19:01","pubTimestamp":1789038071,"startTime":"0","endTime":"0","summary":"徕博科（Labcorp）在2026年投资者日活动中，着重阐述了其战略优先事项，旨在驱动持久增长并提升股东价值。该公司通过一系列举措，明确了未来发展的核心路径。这些优先事项聚焦于增强核心竞争力、优化运营效率，以及深化对客户和患者的服务承诺。管理层在会上详细介绍了如何利用创新技术、扩大诊断服务范围，并强化数据驱动决策能力，以巩固市场地位。此外，徕博科还强调了资本配置策略，包括对高增长领域的投资和股东回报机制的完善，力求在动态变化的医疗健康环境中实现长期稳健的财务表现。此次投资者日传递出的信息表明，公司正致力于通过清晰的战略布局和执行力，为所有利益相关方创造可持续的价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251131958.USD","LU0251142724.SGD","LH","BK4585","LU1059921491.USD","LU0742534661.SGD","BK4588","BK4550","BK4196","LU2237438978.USD","LU0048573561.USD","LU0006061336.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121225568","title":"徕博科收购Mlm Medical Labs，强化全球中心实验室与临床试验生物标志物能力","url":"https://stock-news.laohu8.com/highlight/detail?id=1121225568","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121225568?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:11","pubTimestamp":1788873105,"startTime":"0","endTime":"0","summary":"徕博科宣布完成对Mlm Medical Labs的收购，这一战略举措显著增强了其在全球中心实验室及生物标志物检测领域的服务能力，为临床试验提供更全面的支持。此次并购聚焦于扩大徕博科在关键领域的布局，尤其是针对复杂生物标志物的分析与验证。通过整合Mlm Medical Labs的专业技术，徕博科得以进一步优化其全球实验室网络，从而提升对制药及生物技术客户的项目响应速度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251131958.USD","LU0742534661.SGD","BK4585","LU1059921491.USD","BK4196","LU0251142724.SGD","LU0048573561.USD","BK4550","BK4588","LH","LU2237438978.USD","LU0006061336.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103312457","title":"徕博科推出首款获FDA批准的血液检测，助力阿尔茨海默病病理筛查覆盖初级与专科诊疗场景","url":"https://stock-news.laohu8.com/highlight/detail?id=1103312457","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103312457?lang=zh_cn&edition=full","pubTime":"2026-08-24 19:05","pubTimestamp":1787569547,"startTime":"0","endTime":"0","summary":"徕博科宣布，将率先推出首款获得美国食品药品监督管理局（FDA）批准的血液检测产品，用于在初级保健和专科医疗环境中检测阿尔茨海默病的病理特征。\n这一里程碑式的举措，标志着阿尔茨海默病诊断方式迎来重大变革。传统上，此类检测通常局限于专科医疗机构，而如今，这一创新检测手段有望深入更广泛的临床场景，让更多患者得以在疾病早期获得关键诊断信息。\n借助这一检测，医生可在日常诊疗中更高效地识别阿尔茨海默病的潜在病理迹象，从而为患者争取宝贵的干预时间。徕博科此举，不仅拓宽了诊断工具的适用范围，也为推动精准医疗在神经退行性疾病领域的落地迈出了坚实一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237438978.USD","BK4585","BK4196","LH","BK4588","LU0048573561.USD","LU0251131958.USD","LU0742534661.SGD","LU1059921491.USD","LU0006061336.USD","BK4550","LU0251142724.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111010241","title":"徕博科高管：ACA相关调整对2026年诊断业务量约30个基点影响的假设仍然合理","url":"https://stock-news.laohu8.com/highlight/detail?id=1111010241","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111010241?lang=zh_cn&edition=full","pubTime":"2026-07-30 21:33","pubTimestamp":1785418412,"startTime":"0","endTime":"0","summary":"徕博科（Labcorp Holdings Inc）高管在最新电话会议中表示，旗下诊断业务因《平价医疗法案》（ACA）相关调整，预计在2026年将面临约30个基点的业务量冲击。这一影响范围的假设，至今仍被视为恰当且适用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251142724.SGD","BK4550","BK4585","LU0251131958.USD","BK4588","LH","LU2237438978.USD","LU0048573561.USD","LU0742534661.SGD","LU0006061336.USD","LU1059921491.USD","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103497852","title":"徕博科高管：肿瘤患者所接受的检测数量远超普通患者，推高每例样本检测量——电话会议披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1103497852","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103497852?lang=zh_cn&edition=full","pubTime":"2026-07-30 21:33","pubTimestamp":1785418388,"startTime":"0","endTime":"0","summary":"在徕博科（Labcorp Holdings Inc）的电话会议上，一位高管指出，肿瘤患者在医院治疗的漫长过程中，通常会接受比普通患者多得多的检测。具体而言，这些患者所接受的检测频次显著高于一般人群，这一趋势直接推动了公司每例样本（Accession）对应检测数量的持续攀升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH","LU0006061336.USD","LU0048573561.USD","LU0742534661.SGD","LU1059921491.USD","LU0251142724.SGD","BK4585","BK4550","LU0251131958.USD","LU2237438978.USD","BK4196","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190044926","title":"徕博科高管：专业检测业务增速持续领先常规检测，预期这一趋势有望延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1190044926","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190044926?lang=zh_cn&edition=full","pubTime":"2026-07-30 21:29","pubTimestamp":1785418189,"startTime":"0","endTime":"0","summary":"徕博科的高管在电话会议中透露，该公司的专业检测业务板块当前正以超越常规检测业务的速度实现增长，且增长的势头颇为强劲。这位高管进一步指出，基于现有态势，他们预计这一差异化趋势将在未来一段时间内得到延续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4550","LU0251131958.USD","BK4588","LU0742534661.SGD","LU1059921491.USD","LU2237438978.USD","LU0251142724.SGD","LH","BK4585","LU0006061336.USD","LU0048573561.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103287053","title":"异动解读 | 徕博科盘前大跌5.43%，诊断实验室部门有机增长不及预期引发担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1103287053","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103287053?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:12","pubTimestamp":1785413547,"startTime":"0","endTime":"0","summary":"徕博科今日盘前大跌5.43%，引发市场广泛关注。消息面上，尽管徕博科公布了优于预期的第二季度业绩并上调了全年利润预期，但投资者将关注点集中在其诊断实验室部门低于预期的有机增长上。竞争对手Quest Diagnostics上周公布的业绩设定了更高标准，令市场对徕博科诊断业务的表现感到失望。从整体业绩来看，徕博科第二季度总营收增长5.8%至37.3亿美元，高于预期的37.1亿美元；经调整后每股收益为4.99美元，高于预期的4.78美元。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166049812","title":"徕博科推出Marker by Labcorp™遗传健康检测组合，拓宽消费者对遗传性风险检测的可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1166049812","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166049812?lang=zh_cn&edition=full","pubTime":"2026-07-27 20:03","pubTimestamp":1785153780,"startTime":"0","endTime":"0","summary":"徕博科（Labcorp Holdings Inc.）近日正式推出Marker by Labcorp™遗传健康检测组合。此举旨在显著拓展消费者对遗传性基因风险检测的获取途径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251142724.SGD","BK4588","BK4196","LU0048573561.USD","LH","LU0742534661.SGD","LU0006061336.USD","BK4585","BK4550","LU0251131958.USD","LU1059921491.USD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193006068","title":"财报前瞻｜徕博科本季度营收预计增6.47%，机构观点偏积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1193006068","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193006068?lang=zh_cn&edition=full","pubTime":"2026-07-24 00:06","pubTimestamp":1784822810,"startTime":"0","endTime":"0","summary":"徕博科将于2026年07月30日盘前披露财报，市场关注收入增速与调整后每股收益的韧性以及产品与合作落地带来的结构性改善。一致预期显示，本季度徕博科营收预计为美元37.11亿，同比增长6.47%；调整后每股收益预计为美元4.78，同比增长14.65%。上一季度徕博科营收为美元35.38亿，同比增长5.76%；毛利率为28.66%；归属于母公司股东的净利润为美元2.78亿，净利率为7.85%；调整后每股收益为美元4.25，同比增长10.68%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜徕博科本季度营收预计增6.47%，机构观点偏积极","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650272189","title":"Labcorp(LH)宣布派发每股0.72美元普通股季度股息","url":"https://stock-news.laohu8.com/highlight/detail?id=2650272189","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650272189?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:58","pubTimestamp":1783677490,"startTime":"0","endTime":"0","summary":"金吾财讯 | 徕博科Labcorp(LH)发布分红公告，公司董事会正式批准最新一期普通股季度现金分红，每股派发 0.72 美元。本次分红确权日设定为 2026 年 8 月 28 日收盘，凡当日登记在册的全体普通股股东均可享有分红权益，实际现金发放时间定于 9 月 11 日。分析人士对此指出，Labcorp 持续维持稳定季度分红标准，反映管理层对中长期全球诊疗、医药研发需求保持乐观，现金流储备足以平衡研发投入、股东分红两大资金需求。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/NjQzZWIwYjMxODE0NDMwMmFiMWMzYWFhZmVlYWI3MGY0MzQwNTkyOTA0MzE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NjQzZWIwYjMxODE0NDMwMmFiMWMzYWFhZmVlYWI3MGY0MzQwNTkyOTA0MzE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302437","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UUP","VIG","BK4588","LU2237438978.USD","LH","BK4585","BK4196","LU0048573561.USD","LU0251142724.SGD","LU1059921491.USD","LU0251131958.USD","LU0006061336.USD","UDN","LU0742534661.SGD","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191592188","title":"徕博科宣布全美上市首款FDA批准基于RNA的居家结直肠癌筛查产品Colosense®","url":"https://stock-news.laohu8.com/highlight/detail?id=1191592188","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191592188?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:01","pubTimestamp":1782126100,"startTime":"0","endTime":"0","summary":"徕博科（Labcorp）宣布，其首款获得美国食品药品监督管理局（FDA）批准的基于RNA技术的居家结直肠癌筛查检测产品Colosense®，现已在美国全国范围内上市。这款创新的非侵入性检测工具，标志着结直肠癌早期筛查领域的一次重要突破，为公众提供了更为便捷、私密的筛查选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0048573561.USD","LU0251131958.USD","LU0251142724.SGD","LU1059921491.USD","BK4585","BK4196","LU2237438978.USD","LH","LU0742534661.SGD","LU0006061336.USD","BK4550","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145365971","title":"Genfit携手Labcorp推出Nashnext®：基于Nis4®无创诊断技术，助力识别高危MASH患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1145365971","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145365971?lang=zh_cn&edition=full","pubTime":"2026-06-09 00:00","pubTimestamp":1780934421,"startTime":"0","endTime":"0","summary":"Genfit公司宣布，其基于自主研发的非侵入性诊断技术Nis4®所打造的Nashnext®检测方案，现已通过Labcorp（徕博科）的Ondemand服务正式推出。该产品旨在帮助识别存在代谢功能障碍相关脂肪性肝炎（MASH）风险的患者。\n此项合作标志着Genfit创新的无创诊断技术在临床可及性方面迈出了重要一步。通过Labcorp广泛的检测服务网络，医疗专业人员能够更便捷地利用Nashnext®，对高危人群进行早期筛查与风险评估，从而有望实现更及时的患者管理和干预。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251131958.USD","BK4196","LH","BK4588","LU0742534661.SGD","LU0006061336.USD","LU1059921491.USD","BK4550","LU2237438978.USD","LU0048573561.USD","BK4585","LU0251142724.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639102624","title":"Labcorp(LH)与肿瘤临床试验联盟达成全美战略合作 扩大结直肠癌基因检测范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2639102624","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639102624?lang=zh_cn&edition=full","pubTime":"2026-05-29 19:29","pubTimestamp":1780054196,"startTime":"0","endTime":"0","summary":"Labcorp将作为独家基因检测提供商，全面支持一项针对新确诊结直肠癌患者及其高危亲属的全国性、多中心大型临床试验。作为本项全国性试验的独家技术支持方，Labcorp将依托其旗下的Invitae基因检测平台，凭借其覆盖全美的实验室网络规模和深厚的伴随诊断学术积累，为所有参与机构提供高质量的生殖系基因检测与多基因联合检测服务。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/YjU2YzAxODc0YzFlOTM1Nzk3MTU1NDIzZDRjODY4MTE1MzM5MTg2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YjU2YzAxODc0YzFlOTM1Nzk3MTU1NDIzZDRjODY4MTE1MzM5MTg2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300983","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4550","LU0251131958.USD","BK4588","LU0742534661.SGD","LU1059921491.USD","LU2237438978.USD","LU0251142724.SGD","LH","BK4585","LU0006061336.USD","LU0048573561.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169430590","title":"徕博科推出Mylabcorp™：一款AI驱动的移动应用，助力用户解读检验报告与追踪长期健康趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=1169430590","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169430590?lang=zh_cn&edition=full","pubTime":"2026-05-20 19:01","pubTimestamp":1779274893,"startTime":"0","endTime":"0","summary":"徕博科（Labcorp）近日正式发布了一款名为Mylabcorp™的全新移动应用程序。该应用由人工智能技术驱动，旨在帮助消费者更清晰地理解实验室检验结果，并长期追踪个人健康趋势的变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1059921491.USD","BK4588","LU0251142724.SGD","BK4550","BK4196","LU0251131958.USD","LU0742534661.SGD","LU2237438978.USD","LU0048573561.USD","LU0006061336.USD","LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176340925","title":"徕博科与Epic深化合作，推动医院及医疗系统诊断整合","url":"https://stock-news.laohu8.com/highlight/detail?id=1176340925","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176340925?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:02","pubTimestamp":1778583779,"startTime":"0","endTime":"0","summary":"徕博科与Epic系统公司宣布扩大合作范围，旨在共同推进诊断服务在各级医院及更广泛的医疗体系中的深度整合。此次合作升级将致力于优化工作流程，提升数据互操作性，并最终改善患者护理体验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1059921491.USD","LU2237438978.USD","LH","BK4550","LU0048573561.USD","BK4588","LU0006061336.USD","LU0742534661.SGD","LU0251131958.USD","BK4196","LU0251142724.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130176453","title":"异动解读 | 徕博科盘前大涨9.80%，因上调全年业绩预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1130176453","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130176453?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:02","pubTimestamp":1777550561,"startTime":"0","endTime":"0","summary":"徕博科（LH）今日盘前股价大幅上涨9.80%，引起了市场的广泛关注。消息面上，徕博科上调了全年利润和营收预期。该公司公布的季度业绩超出预期，主要得益于诊断检测需求保持稳定。其常规和专科诊断检测业务助力核心业务增长，缓解了药物研发服务部门因生物技术支出放缓带来的冲击。具体来看，徕博科目前预计全年经调整后每股收益将在17.70美元至18.35美元之间，高于此前预测。同时，预计2026年营收将在146.5亿至148.0亿美元之间，同样高于此前预期。公司首席执行官表示，强劲的业绩得益于诊断业务和中央实验室业务的持续增长势头，公司还在扩展专科服务和投资自动化与人工智能领域。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134162431","title":"财报前瞻｜徕博科本季营收预计增3.16%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1134162431","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134162431?lang=zh_cn&edition=full","pubTime":"2026-04-23 10:32","pubTimestamp":1776911529,"startTime":"0","endTime":"0","summary":"徕博科将于2026年04月30日美股盘前公布最新季度财报，市场预期本季收入与盈利保持温和增长，关注费用效率与新业务协同成效。市场一致预期显示，本季度徕博科营收预计为35.05亿美元，同比增3.16%；息税前利润预计为4.98亿美元，同比增6.03%；调整后每股收益预计为4.09美元，同比增9.40%；上季度官方披露中未见针对本季度的毛利率与净利率量化指引，相关一致预期亦未形成明确口径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜徕博科本季营收预计增3.16%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627443137","title":"Labcorp(LH)与AWS合作推出用于阿尔茨海默病研究的AI数据平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2627443137","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627443137?lang=zh_cn&edition=full","pubTime":"2026-04-14 19:40","pubTimestamp":1776166835,"startTime":"0","endTime":"0","summary":"据介绍，该平台将Labcorp的诊断和基因组数据集与医疗索赔数据相结合，并利用人工智能分析去标识化的医疗保健信息，旨在使研究阿尔茨海默病的科研人员和生物制药公司的数据准备时间从数月缩短至数分钟。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299165","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTY","BK4196","BK4550","CHAT","LU0251131958.USD","BK4588","LU0742534661.SGD","LU1059921491.USD","LU2237438978.USD","LU0251142724.SGD","LH","BK4585","AGIX","LU0006061336.USD","LU0048573561.USD","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131884848","title":"徕博科携手AWS与Datavant推出AI驱动真实世界数据平台，加速阿尔茨海默病研究进程","url":"https://stock-news.laohu8.com/highlight/detail?id=1131884848","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131884848?lang=zh_cn&edition=full","pubTime":"2026-04-14 19:06","pubTimestamp":1776164763,"startTime":"0","endTime":"0","summary":"徕博科宣布与亚马逊云服务（AWS）及医疗数据连接技术公司Datavant达成合作，共同推出一款由人工智能驱动的真实世界数据平台。该平台旨在整合与分析大规模现实医疗数据，以显著提升阿尔茨海默病及相关神经退行性疾病的研究效率。\n通过运用先进的人工智能技术，平台能够对去标识化的真实世界数据进行深度挖掘与模式识别，帮助研究人员更快速地识别疾病生物标志物、评估治疗方法的有效性，并优化临床试验设计。这一创新合作有望为阿尔茨海默病的药物研发与精准医疗开辟新的路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251142724.SGD","BK4588","BK4196","LU0048573561.USD","LH","LU0742534661.SGD","LU0006061336.USD","BK4585","BK4550","LU0251131958.USD","LU1059921491.USD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510472920","title":"徕博科2024财年实现净利润7.46亿美元，同比增加96.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510472920","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510472920?lang=zh_cn&edition=full","pubTime":"2025-02-10 00:00","pubTimestamp":1739116854,"startTime":"0","endTime":"0","summary":"2月10日，徕博科公布财报，公告显示公司2024财年净利润为7.46亿美元，同比增加96.83%；其中营业收入为130.09亿美元，同比增加6.96%，每股基本收益为8.89美元。从资产负债表来看，徕博科总负债103.13亿美元，其中短期债务11.85亿美元，资产负债比为1.79，流动比率为1.45。机构评级：截至2025年2月10日，当前有16家机构对徕博科目标价做出预测，其中目标均价为271.81美元，其中最低目标价为240.00美元，最高目标价为293.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210000129abc86720&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210000129abc86720&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.labcorp.com","stockEarnings":[{"period":"1week","weight":0.0136},{"period":"1month","weight":-0.0738},{"period":"3month","weight":0.0736},{"period":"6month","weight":0.1256},{"period":"1year","weight":0.0733},{"period":"ytd","weight":0.2281}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Labcorp Holdings Inc.是特拉华州的一家公司，成立于1971年。公司是一家领先的全球生命科学公司，已在指导患者护理方面深入整合。公司通过其LabCorp诊断（LCD）和Covance药物开发（CDD）部门提供全面的临床实验室和端到端药物开发服务。LabCorp定位于研究和护理交付的融合，以实现更精确和个性化的医疗保健，将世界一流的诊断和药物开发能力结合在一起。","yearOnYearQuotes":[{"month":1,"riseRate":0.645161,"avgChangeRate":0.026972},{"month":2,"riseRate":0.612903,"avgChangeRate":0.024969},{"month":3,"riseRate":0.612903,"avgChangeRate":-0.00762},{"month":4,"riseRate":0.677419,"avgChangeRate":0.052186},{"month":5,"riseRate":0.516129,"avgChangeRate":0.00838},{"month":6,"riseRate":0.59375,"avgChangeRate":0.027065},{"month":7,"riseRate":0.5,"avgChangeRate":0.011975},{"month":8,"riseRate":0.46875,"avgChangeRate":-0.026932},{"month":9,"riseRate":0.4375,"avgChangeRate":-0.00589},{"month":10,"riseRate":0.548387,"avgChangeRate":-0.003333},{"month":11,"riseRate":0.677419,"avgChangeRate":0.00863},{"month":12,"riseRate":0.709677,"avgChangeRate":0.014463}],"exchange":"NYSE","name":"徕博科","nameEN":"Labcorp Holdings Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"徕博科(LH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供徕博科(LH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"徕博科,LH,徕博科股票,徕博科股票老虎,徕博科股票老虎国际,徕博科行情,徕博科股票行情,徕博科股价,徕博科股市,徕博科股票价格,徕博科股票交易,徕博科股票购买,徕博科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"徕博科(LH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供徕博科(LH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}